MFC
Financials
Valuation Metrics
MFC's Market Cap is ₩232B. At end of 2025 it was ₩300B. Ranked #2248 of 2,421 in KR market (top 93%), #1483 of 1,640 on KOSDAQ (top 90%), #222 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 96%) by Market Cap.
Investment Metrics(as of 2026-09-18)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 23.24B KRW | KR#2,248/2,421 Sec#222/231 |
| Revenue | 18.70B KRW | KR#2,155/2,421 Sec#158/231 |
| Net Income | -609.1M KRW | KR—/2,421 Sec—/231 |
| Total Assets | 33.94B KRW | KR#2,312/2,421 Sec#215/231 |
| Net Assets | 29.18B KRW | KR#2,183/2,421 Sec#197/231 |
| Employees | 70 | KR#1,873/2,421 Sec#161/231 |
| Value | ||
| P/B | 0.80x | KR#1,260/2,421 Sec#78/231 |
| P/S | 1.24x | KR#1,519/2,421 Sec#87/231 |
| Profitability | ||
| ROE | -2.09% | KR#1,695/2,421 Sec#118/231 |
| ROA | -1.79% | KR#1,736/2,421 Sec#122/231 |
| Op. Margin | -3.00% | KR#1,777/2,421 Sec#120/231 |
| Revenue Growth | 0.95% | KR#1,466/2,421 Sec#145/231 |
| Financial Health | ||
| Debt Ratio | 16.34% | KR#282/2,421 Sec#42/231 |
| Total Debt | 2.99B KRW | KR#1,871/2,421 Sec#179/231 |
| Cash | 5.15B KRW | KR#1,991/2,421 Sec#184/231 |
| Current Ratio | 3.88x | KR#407/2,421 Sec#64/231 |
| Performance | ||
| 1Y Return | -34.10% | KR#1,683/2,421 Sec#134/231 |
| 1M Return | -1.46% | KR#1,405/2,421 Sec#107/231 |
| From 52W High | -40.29% | KR#940/2,421 Sec#64/231 |
| 1Y MDD | -42.79% | KR#685/2,421 Sec#51/231 |
| Trading | ||
| Volume | 92,707 shares | KR#816/2,421 Sec#74/231 |
| Trading Value | 251.1M KRW | KR#1,186/2,421 Sec#119/231 |
| Foreign Own. | 1.14% | KR#1,974/2,421 Sec#194/231 |
| Per Share | ||
| EPS | -71 KRW | KR—/2,421 Sec—/231 |
| BPS | 3,396 KRW | KR#1,773/2,421 Sec#132/231 |
Company Info
MFC, established in 2008, is a specialized company in Active Pharmaceutical Ingredient (API) and material development and manufacturing, listed on the KOSDAQ market as a technology growth company in 2024. Utilizing organic synthesis, mass production, and new crystallization technologies, MFC develops and mass produces APIs, Key Starting Materials (KSM), and Pharmaceutical Intermediates (PI). The company produces and sells APIs for various therapeutic areas, including cardiovascular, digestive, and anti-inflammatory and analgesic treatments. MFC is pursuing market preemption by securing intellectual property rights for new crystal forms and salts in the improved new drug raw materials sector. The company is headquartered in Hwaseong-si, Gyeonggi-do.